HOW TO PERFORM A TEST

Tests performed entirely in Italy
(two headquarters: Rome and Milan)

Sample collection

Sample shipment

Report receiving

ONCO NEXT RISK
Next Generation Oncology Diagnostics

The possibility to detect subjects at risk of developing a neoplasm related to hereditary mutations represents today the best method to reach an early diagnosis and to reduce mortality actualizing personalized surveillance programs.

Members of families with a high hereditary risk, and in particular those who have been directly affected by a neoplasm, can request genetic counselling and discuss their own genetic-clinical situation with the geneticist.

ONCO NEXT RISK
Next Generation Oncology Diagnostics

Test for the research of germline mutations predisposing to the development of tumors

ONCO NEXT LIQUID
Next Generation Oncology Diagnostics

Test for the study of circulating free tumor DNA in peripheral blood for the research of somatic mutations

ONCO NEXT TISSUE
Next Generation Oncology Diagnostics

Test for the molecular characterization of tumor tissues for the research of somatic mutations

WHY CHOOSE ONCONEXT™ BY GENOMA GROUP

- Tests performed entirely in Italy (two headquarters: Rome and Milan)
- Rapid reporting: 15 working days
- 20 years of experience in genetics and molecular biology
- Team of medical geneticists
- Laboratories equipped with the most innovative technologies and advanced quality systems
- Availability on all Italian territory

Onconext Risk T ENG rev.00

design by evermind.it

ONCO NEXT
Next Generation Oncology Diagnostics

www.laboratoriogenoma.eu
www.onconext.it

ROMA
Laboratories and Medical Offices

Via Castel Giubileo, 11 – 00138 Roma (RM)
Tel.: + (39) 06 8811270 (6 PBX lines)
Fax: +(39) 06 64492025
E-mail: info@laboratoriogenoma.eu

MILANO
Laboratories and Medical Offices

Via Enrico Cialdini, 16 (Affori Centre) – 20161 Milano (MI)
Tel.: + (39) 02 39297626 (12 PBX lines)
Fax: + (39) 02 392976261
E-mail: info@genomamilano.it

ONCO NEXT RISK
Next Generation Oncology Diagnostics

Genetic tests for the study of the predisposition to the development of inherited tumors

PREVENTION
PERSONALIZED SUPERVISION
EARLY DIAGNOSIS

ONCONEXT RISK GENETIC TESTS ARE DIAGNOSTIC TESTS THAT ALLOW PERFORMING A MULTIPLE GENETIC ANALYSIS FOR THE DETECTION OF THE PREDISPOSITION TO HEREDITARY TUMORS.

The genes analyzed in ONCONEXT RISK tests codify for oncosuppressor proteins with the role of tumor suppressor genes. Patients carriers of germline mutations on these genes, having inherited a copy of the mutated gene, own a greater predisposition of developing, precociously and more easily than the general population, the tumor related to the mutated gene.



ONCONEXT RISK TESTS ARE ADVISABLE IN PERSONALIZED SURVEILLANCE PROGRAMS OF PATIENTS WITH PERSONAL OR FAMILY HISTORY OF:

- Tumors at an early age
- Multiple tumors in the same patient
- Suspected or proven predisposition to hereditary tumors

ONCONEXT™ RISK TESTS ARE AVAILABLE IN A TARGETED VERSION FOR DIFFERENT TYPES OF TUMOR

BREAST
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MRE11A, MUTYH, NBN, NF1, PALB2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53

OVARIAN/UTERINE
BRCA1, BRCA2, BRIP1, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53

COLON
APC, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, PTEN, SMAD4, STK11, TP53

GASTRIC
APC, BMPR1A, CDH1, EPCAM, MLH1, MSH2, MSH6, PMS2, STK11, SMAD4, TP53

PANCREAS
APC, ATM, BMPR1A, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53

MELANOMA
BAP1, BRCA2, CDK4, CDKN2A, MITF, PTEN, RB1, TP53

PROSTATE
ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51D, TP53

CEREBRAL
AIP, ALK, APC, CDKN1B, CDKN2A, DICER1, MEN1, MLH1, MSH2, MSH6, NBN, NF1, NF2, PHOX2B, PMS2, PRKAR1A, PTCH1, PTEN, SMARCA4, SMARCB1, SMARCE1, SUFU, TP53, TSC1, TSC2, VHL

RENAL
BAP1, EPCAM, FH, FLCN, MET, MITF, MLH1, MSH2, MSH6, PMS2, PTEN, SDHA, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL

PHEOCHROMOCYTOMA / PARAGANGLIOMA
FH, MAX, MEN1, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL

ONCOSCREENING COMPLETE

GENE	Breast	Ovarian/Uterine	Colorectal	Gastric	Pancreas	Prostate	Melanoma	Cerebral	Renal	Pheochromocytoma/ Paraganglioma	Others
AIP								•			
ALK								•			
APC			•	•	•			•			
ATM	•				•	•					
BAP1							•		•		
BARD1	•										
BMPR1A			•	•	•						
BRCA1	•	•			•	•					
BRCA2	•	•			•	•	•				
BRIP1	•	•									
BUB1B											•
CDC73											•
CDH1	•		•	•							
CDK4							•				
CDKN1B								•			
CDKN2A					•		•	•			
CEBPA											•
CHEK2	•		•			•					
DICER1								•			
EGFR											•
EPCAM		•	•	•	•	•			•		
EXT1											•
EXT2											•
FH									•	•	
FLCN									•		
GALNT12											•
GATA2											•
GPC3											•
GREM1			•								
HNF1A											•
HOXB13						•					
HRAS											•
KIT											•
MAX										•	
MEN1								•		•	
MET									•		
MITF							•		•		
MLH1		•	•	•	•	•		•	•		
MRE11A	•										
MSH2		•	•	•	•	•		•	•		

GENE	Breast	Ovarian/Uterine	Colorectal	Gastric	Pancreas	Prostate	Melanoma	Cerebral	Renal	Pheochromocytoma/ Paraganglioma	Others
MSH6		•	•	•	•	•		•	•		
MUTYH	•		•								
NBN	•					•		•			
NF1	•							•		•	
NF2								•			
NSD1											•
PALB2	•	•			•	•					
PHOX2B								•			
PMS1											•
PMS2		•	•	•	•	•		•	•		
POLD1			•								
PRF1											•
PRKAR1A								•			
PTCH1								•			
PTEN	•	•	•				•	•	•		
RAD50	•										
RAD51C	•	•									
RAD51D	•	•				•					
RB1							•				
RET										•	
RHBDF2											•
RUNX1											•
SBDS											•
SDHA									•	•	
SDHAF2										•	
SDHB									•	•	
SDHC									•	•	
SDHD									•	•	
SMAD4			•	•							
SMARCA4								•			
SMARCB1								•			
SMARCE1								•			
STK11	•	•	•	•							
SUFU								•			
TMEM127										•	
TP53	•	•	•	•	•	•	•	•	•		
TSC1								•	•		
TSC2								•	•		
VHL								•	•	•	
WT1											•

IT IS SUFFICIENT A PERIPHERAL BLOOD SAMPLE OF 3-5 ML